Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen

被引:53
作者
Chen, ZC
Moayeri, M
Zhou, YH
Leppla, S
Emerson, S
Sebrell, A
Yu, FJ
Svitel, J
Schuck, P
St Claire, M
Purcell, R
机构
[1] NIAID, Hepatitis Viruses Sect, Infect Dis Lab, NIH, Bethesda, MD 20892 USA
[2] NIAID, Mol Hepatitis Sect, Infect Dis Lab, Bethesda, MD 20892 USA
[3] NIAID, Bacterial Toxins & Therapeut Sect, Bethesda, MD 20892 USA
[4] NIH, Prot Biophys Resource, Bethesda, MD 20892 USA
[5] Bioqual, Rockville, MD USA
关键词
D O I
10.1086/500148
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Four single-chain variable fragments (scFvs) against protective antigen (PA) and 2 scFvs against lethal factor (LF) of anthrax were isolated from a phage display library generated from immunized chimpanzees. Only 2 scFvs recognizing PA (W1 and W2) neutralized the cytotoxicity of lethal toxin in a macrophage lysis assay. Full-length immunoglobulin G (IgG) of W1 and W2 efficiently protected rats from anthrax toxin challenge. The epitope recognized by W1 and W2 was conformational and was formed by C-terminal amino acids 614 735 of PA. W1 and W2 each bound to PA with an equilibrium dissociation constant of 4 x 10(-11) mol/L to 5 x x 10(-11) mol/L, which is an affinity that is 20-100-fold higher than that for the interaction of the receptor and PA. W1 and W2 inhibited the binding of PA to the receptor, suggesting that this was the mechanism of protection. These data suggest that W1 and W2 chimpanzee monoclonal antibodies may serve as PA entry inhibitors for use in the emergency prophylaxis against and treatment of anthrax.
引用
收藏
页码:625 / 633
页数:9
相关论文
共 40 条
[1]  
Adams GP, 1998, CANCER RES, V58, P485
[2]   The role of antibody concentration and avidity in antiviral protection [J].
Bachmann, MF ;
Kalinke, U ;
Althage, A ;
Freer, G ;
Burkhart, C ;
Roost, HP ;
Aguet, M ;
Hengartner, H ;
Zinkernagel, RM .
SCIENCE, 1997, 276 (5321) :2024-2027
[3]   Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies [J].
Brossier, F ;
Lévy, M ;
Landier, A ;
Lafaye, P ;
Mock, M .
INFECTION AND IMMUNITY, 2004, 72 (11) :6313-6317
[4]   Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors [J].
Cirino, NM ;
Sblattero, D ;
Allen, D ;
Peterson, SR ;
Marks, JD ;
Jackson, PJ ;
Bradbury, A ;
Lehnert, BE .
INFECTION AND IMMUNITY, 1999, 67 (06) :2957-2963
[5]   Anthrax toxin [J].
Collier, RJ ;
Young, JAT .
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 2003, 19 :45-70
[6]   THE HUMAN-IMMUNOGLOBULIN V-H REPERTOIRE [J].
COOK, GP ;
TOMLINSON, IM .
IMMUNOLOGY TODAY, 1995, 16 (05) :237-242
[7]  
Ehrlich P H, 1990, Hum Antibodies Hybridomas, V1, P23
[8]  
EHRLICH PH, 1988, CLIN CHEM, V34, P1681
[9]   Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: Recovery from a long-term-nonprogressor SIV-Infected macaque [J].
Glamann, J ;
Burton, DR ;
Parren, PWHI ;
Ditzel, HJ ;
Kent, KA ;
Arnold, C ;
Montefiori, D ;
Hirsch, VM .
JOURNAL OF VIROLOGY, 1998, 72 (01) :585-592
[10]  
Harrison JL, 1996, METHOD ENZYMOL, V267, P83